Mycophenolate Mofetil, Sirolimus, Tacrolimus, and Thymoglobulin Combination Therapy

This is a combination immunosuppressive regimen primarily used in kidney transplantation for the prevention of organ rejection, especially in high-risk patients. It comprises four distinct immunosuppressants, each targeting different aspects of the immune response:

1. Mycophenolate mofetil (MMF): An antimetabolite that inhibits T and B cell proliferation. 2. Sirolimus: An immunosuppressant that inhibits T cell activation and proliferation by targeting mTOR. 3. Tacrolimus: A calcineurin inhibitor that prevents T cell activation. 4. Thymoglobulin (Anti-thymocyte globulin, rabbit): A polyclonal antibody that depletes T cells.

This multi-drug approach provides multi-targeted immunosuppression:

• Thymoglobulin typically provides initial T-cell depletion (induction therapy).
• Tacrolimus inhibits calcineurin, preventing T-cell activation.
• Mycophenolate mofetil inhibits purine synthesis, affecting T and B cell proliferation.
• Sirolimus inhibits the mammalian target of rapamycin (mTOR), affecting T-cell proliferation.

While offering robust immunosuppression crucial for patients at high immunological risk for rejection, such intensive immunosuppression also carries significant risks of infection and other adverse effects.